XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Apr. 17, 2023
Jun. 30, 2022
Cover [Abstract]      
Entity Registrant Name Minerva Neurosciences, Inc.    
Entity Central Index Key 0001598646    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Document Type 10-K/A    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Amendment Flag true    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Title of 12(b) Security Common Stock, $0.0001 par value per share    
Trading Symbol NERV    
Security Exchange Name NASDAQ    
Entity Tax Identification Number 26-0784194    
Entity File Number 001-36517    
Entity Address, Address Line One 1500 District Avenue    
Entity Address, City or Town Burlington    
Entity Address, State or Province MA    
Entity Incorporation, State or Country Code DE    
Entity Address, Postal Zip Code 01803    
City Area Code 617    
Local Phone Number 600-7373    
Document Transition Report false    
Documents Incorporated by Reference [Text Block] None.    
Document Annual Report true    
Entity Current Reporting Status Yes    
Entity Public Float     $ 17.1
Entity Common Stock, Shares Outstanding   5,340,193  
Entity Shell Company false    
Entity Emerging Growth Company false    
Entity Small Business true    
Entity Interactive Data Current Yes    
ICFR Auditor Attestation Flag false    
Amendment Description Minerva Neurosciences, Inc. (the “Company,” “Minerva,” “we,” “us” or “our”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to amend our Annual Report on Form 10-K for the year ended December 31, 2022, originally filed with the Securities and Exchange Commission (the “SEC”) on March 8, 2023 (the “Original 10-K”), to (i) include the information required by Items 10 through 14 of Part III of Form 10-K and (ii) amend Item 15 of Part IV of the Original 10-K to update the exhibit list. The information required by Items 10 through 14 of Part III of Form 10-K was previously omitted from the Original 10-K in reliance on General Instruction G(3) to Form 10-K, which permits the information in the above referenced items to be incorporated in the Form 10-K by reference from our definitive proxy statement if such statement is filed no later than 120 days after our fiscal year-end. We are filing this Amendment to include Part III information in our Form 10-K because a definitive proxy statement containing such information may not be filed by Minerva within 120 days after the end of the fiscal year covered by the Form 10-K. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Part III, Items 10 through 14 of the Original 10-K are hereby amended and restated in their entirety. Additionally, in accordance with Rules 12b-15 and 13a-14 under the Exchange Act, we have amended Part IV, Item 15 to include currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Since no new financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Similarly, since no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted. Except for the changes to Part III and Item 15 of Part IV, including the filing of related certifications added to the exhibit list in Part IV, this Amendment makes no changes to the Original 10-K. This Amendment does not reflect events occurring after the filing of the Original 10-K or modify disclosures affected by subsequent events. Terms used but not otherwise defined in this Amendment have such meaning as ascribed to them in the Original 10-K. As disclosed in the Original 10-K, on June 17, 2022, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a one-for-eight (1-for-8) reverse stock split of our outstanding common stock (the “Reverse Stock Split”). All historical share and per share amounts reflected in this Amendment have been adjusted to reflect the Reverse Stock Split. The par value of our common stock was not adjusted as a result of the Reverse Stock Split.